The India Biologics Market is expected to benefit from continued expansion of biopharmaceutical manufacturing infrastructure. Mammalian cell cultures currently represent the largest source segment, accounting for about 62% of the market, while microbial sources are identified as the fastest-growing category.

Hospitals represent the largest end-user segment, holding approximately 52% of the market, while pharmaceutical companies are experiencing rapid growth as investment in biologics R&D and manufacturing increases.

North America's biotechnology expertise and India's cost-effective manufacturing capabilities are also creating opportunities for international collaboration and outsourcing. Strategic partnerships, technology transfers, and local production can help expand India's role in the global biologics ecosystem.

Major companies identified in the market include AbbVie, Roche, Amgen, Johnson & Johnson, Novartis, Pfizer, Merck & Co., Bristol-Myers Squibb, and Gilead Sciences.

With the market projected to reach USD 166.91 billion by 2035, continued progress in monoclonal antibodies, vaccines, biosimilars, cell and gene therapies, personalized medicine, and biomanufacturing is expected to create substantial opportunities across India's biologics industry.